A Rhode Island overview of physician-supervised GLP-1 treatment through Astra, including local access context and the cities we cover. Every statistic on this page links to its source.
31.1% of Rhode Island adults had obesity in 2024 (CDC BRFSS) 4, and the state's rate has climbed across five straight reported survey years — 30.1% in 2020, 30.1% in 2021, 30.8% in 2022, 31.6% in 2023, 31.1% in 2024 4, with no suppression issue at any point.
Rhode Island is the rare state where Medicaid covers these drugs for weight loss right now and stops soon: an EOHHS memorandum dated August 5, 2026 ends that coverage on October 1, 2026 1.
Today, Rhode Island Medicaid's "Weight Management Agents" drug class covers GLP-1s for weight loss, but narrowly. In the Fee-for-Service Preferred Drug List updated 6/16/2026, Wegovy is the only "preferred" agent; Saxenda, Zepbound, Foundayo (orforglipron), Wegovy HD, and Wegovy tablets are "non-preferred," and the entire class requires manual Clinical Prior Authorization before any of it is covered 23.
That access ends October 1, 2026. Per an RI EOHHS memorandum dated August 5, 2026 ("GLP-1 State Budget Guidance"), issued pursuant to the Rhode Island SFY2027 Enacted Budget, Rhode Island Medicaid will stop covering Foundayo, Saxenda, Wegovy, and Zepbound when prescribed solely for weight loss 1. Members currently on these drugs for weight loss may no longer be able to obtain them through Medicaid after that date, unless continued use is medically necessary for a non-weight-loss indication, which requires a new prior authorization with clinical documentation 1. EPSDT protections are preserved for members under 21 1.
Diabetes-labeled GLP-1s — Ozempic, Trulicity, Mounjaro, Byetta, Victoza and the rest of the separate "GLP-1 Receptor Agonists" PDL class — are not affected 12. This cut targets weight-loss-only prescribing specifically.
Astra's price in Rhode Island is the price everywhere else we operate: $68 a month for compounded semaglutide and $118 a month for compounded tirzepatide, both on 12-month plans billed annually at $816 and $1,416, the same at every dose. There is no Rhode Island price list, no regional surcharge, and no local discount.
Verified local clinic pricing for the capital belongs on the Providence city page rather than here — see that page for the market comparison.
Rhode Island's uninsured rate is 4.6% (ACS 2024 1-year) 7, one of the lowest of any state we have built a page for. Median household income is $87,796 on the ACS 2020–2024 5-year series 7 — a different vintage than the uninsured figure, which is worth noting when the two numbers sit next to each other.
That means most readers here are navigating employer or Medicaid coverage rules, and the October 1 Medicaid cutback specifically, rather than defaulting to cash-pay the way higher-uninsured states do. Telehealth is the fast, no-clinic-visit option for the two groups this page actually serves: people who lose Medicaid coverage for weight-loss prescribing on October 1 and need a next step, and people whose employer plan does not cover GLP-1s at all. Specialist and access-gap detail for the capital is on the Providence city page.
Astra's model is telehealth intake with a licensed prescriber, and compounded-drug and e-prescribing rules are set by state medical and pharmacy boards, which have been changing through 2025-2026. The licensing authority here is the Rhode Island Board of Medical Licensure and Discipline.
TODO — Rhode Island's specific telehealth and e-prescribing rules for GLP-1 prior authorization and any controlled-substance handling have not been independently verified for this page. We are not asserting a specific state rule beyond Astra's general telehealth model until that research is done, and we are not linking a board bulletin URL we have not been given.
Astra serves patients in all 50 states, Rhode Island included — Providence and every other community in the state, with no in-person visit required.
Astra treats patients in Rhode Island through state-licensed physicians.
Providence holds about 17.5% of Rhode Island's population and has its own higher, separately sourced obesity rate — 34.4%, CDC PLACES 2025 on BRFSS 2023 data — so it gets its own page rather than a rehash here.
Yes, but narrowly, and that's about to change. Today, Rhode Island Medicaid's Weight Management Agents drug class covers GLP-1s for weight loss with Wegovy as the sole "preferred" option; Saxenda, Zepbound, Foundayo, Wegovy HD, and Wegovy tablets are "non-preferred," and the entire class requires manual Clinical Prior Authorization before any of it is covered. Starting October 1, 2026, per an RI EOHHS memo dated August 5, 2026 tied to the state's SFY2027 budget, Rhode Island Medicaid will stop covering any of these drugs when prescribed solely for weight loss. Diabetes-labeled GLP-1s (Ozempic, Mounjaro, Trulicity, etc.) are a separate PDL class and are not affected.
If you're on Wegovy, Zepbound, Saxenda, or Foundayo through Rhode Island Medicaid for weight loss, coverage ends that day unless your prescriber can document the drug is medically necessary for a different, non-weight-loss indication and gets a new prior authorization approved. Members under 21 keep EPSDT protections. If neither applies, you'll need another way to pay or another way to get the medication.
No — and that's deliberate. Astra is a telehealth provider, not a local clinic, so our price doesn't change by state or by dose: $68/month for semaglutide, $118/month for tirzepatide, both on 12-month plans, the same in Providence as anywhere else in the country.
No — Astra's care model is fully telehealth: online intake, licensed-clinician review, and shipped medication, no clinic visit required. (Rhode Island's specific telehealth prescribing rules beyond this general model haven't been independently verified for this page yet.)
Yes. Astra is licensed to serve patients in all 50 states, including Rhode Island.
Last reviewed:
Educational information, not medical advice. Treatment requires evaluation by a licensed physician.